Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Clinical trial NCT06093841 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06093841
Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse Follicular Lymphoma Grade 3B High-grade B-cell Lymphoma Mediastinal B-Cell Diffuse Large Cell Lymphoma

Start date: 2023-11-03
Primary completion: 2024-01-21
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.